ANI Pharmaceuticals Inc

BSFA

Company Profile

  • Business description

    ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

  • Contact

    210 Main Street West
    BaudetteMN56623
    USA

    T: +1 218 634-3500

    E: [email protected]

    https://www.anipharmaceuticals.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    897

Stocks News & Analysis

stocks

Nvidia earnings: Another stellar quarter with no signs of a slowdown

Nvidia remains at the heart of the AI ecosystem.
stocks

Chart of the Week: Software selloff creates opportunity for these two stocks

Can AI disrupt the software business model?
stocks

Market is misinterpreting AI impact on cheap ASX share

Unwarranted sell-off with shares down by half in three months.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,408.7027.40-0.29%
CAC 408,622.3963.320.74%
DAX 4025,283.54107.600.43%
Dow JONES (US)49,482.15307.650.63%
FTSE 10010,816.8010.390.10%
HKSE26,381.02384.70-1.44%
NASDAQ23,152.08288.391.26%
Nikkei 22558,753.39170.270.29%
NZX 50 Index13,670.71145.131.07%
S&P 5006,946.130.000.00%
S&P/ASX 2009,175.3027.60-0.30%
SSE Composite Index4,146.630.60-0.01%

Market Movers